

**Maximizing the possibilities in the evolving  
treatment paradigm for R/R follicular  
lymphoma: From optimal sequencing to  
shared decision-making**

# Disclaimer

- *Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions*
- *The presenting faculty have been advised by USF Health and touchIME to ensure that they disclose any such references made to unlabelled or unapproved use*
- *No endorsement by USF Health and touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in USF Health and touchIME activities*
- *USF Health and touchIME accept no responsibility for errors or omissions*

# Expert panel



**Dr Matthew Lunning**

University of Nebraska Medical Center,  
Omaha, NE, USA



**Prof. Charalambos Andreadis**

Helen Diller Family Comprehensive  
Cancer Center, UCSF,  
San Francisco, CA, USA



**Dr Tara Graff**

Mission Cancer and Blood,  
Des Moines, IA, USA



# Agenda

**What does the latest evidence for novel therapies tell us about the evolving treatment paradigm for R/R FL?**


**Why is incorporating patient preferences and shared decision-making important for R/R FL treatment selection in the era of BsAb and CAR T-cell therapies?**

**How should treatment sequencing in R/R FL be approached?**



**What does the latest evidence for novel therapies  
tell us about the evolving treatment  
paradigm for R/R FL?**


# The R/R FL treatment landscape has evolved in recent years



BTK, Bruton's tyrosine kinase; CAR, chimeric antigen receptor; EZH2, enhancer of zeste homolog 2; R/R FL, relapsed/refractory follicular lymphoma; SC, subcutaneous; tx, treatment. 1. FDA. 2020. Available at: <https://bit.ly/4bldA3X> (accessed 21 May 2024); 2. FDA. 2022. Available at: <https://bit.ly/3URVsgL> (accessed 21 May 2024); 3. FDA. 2024. Available at: <https://bit.ly/3QR8nyk> (accessed 21 May 2024); 4. Targeted Oncology. 2024. Available at: <https://bit.ly/3QTC6es> (accessed 21 May 2024); 5. FDA. 2021. Available at: <https://bit.ly/3yrpXCp> (accessed 21 May 2024); 6. FDA. 2022. Available at: <https://bit.ly/3QWa91b> (accessed 21 May 2024); 7. FDA. 2024. Available at: <https://bit.ly/44UqhG1> (accessed 21 May 2024); 8. FDA. 2024. Available at: <https://bit.ly/45GW9OX> (accessed 28 June 2024).

**Why is incorporating patient preferences and shared decision-making important for R/R FL treatment selection in the era of BsAb and CAR T-cell therapies?**


# Multiple factors influence treatment decisions in FL



CRS, cytokine release syndrome; FL, follicular lymphoma; ICANS, immune effector cell-associated neurotoxicity syndrome; QoL, quality of life.

1. Qualls D, Salles G. *Haematologica*. 2022;107:19–34; 2. Skarbnik AZ, Patel K. *Front Oncol*. 2023;13:1120358; 3. Gurumurthi A, et al. *Blood Adv*. 2023;7:5713–6.





**How should treatment sequencing  
in R/R FL be approached?**

# Treatment sequencing is challenging in R/R FL

Lack of published outcome data or limited follow-up available<sup>1,2</sup>

No head-to-head trials comparing recently approved agents<sup>1-3</sup>

Limited knowledge of how treatment affects disease biology and therefore response to next class of agent<sup>2</sup>



No biological insights or biomarkers from clinical trials to help guide patient selection<sup>1-3</sup>

Few patients who have received BsAbs or CAR T-cells have been enrolled in trials for later lines of therapy<sup>1</sup>

Variation in treatment accessibility<sup>1</sup>

BsAb, bispecific antibody; CAR, chimeric antigen receptor; R/R FL, relapsed/refractory follicular lymphoma.

1. Linton KM, et al. *Hematol Oncol.* 2023;1-17; 2. Qualls D, Salles G. *Haematologica.* 2022;107:19-34; 3. Chen CJ, et al. *Cancers (Basel).* 2023;15:4483.